Toxys and Charles River expand non-animal toxicology testing partnership

Toxys and Charles River are expanding access to two in-vitro toxicity testing platforms following OECD recognition of ToxTracker.

Toxys and Charles River Laboratories are expanding their collaboration to increase access to two in-vitro testing technologies for assessing genotoxicity and developmental toxicity, supporting the adoption of New Approach Methodologies (NAMs) in pharmaceutical safety assessment.

Under the expanded agreement, Charles River will offer ToxTracker through its facility in Den Bosch, the Netherlands, under a licensing arrangement. It will also provide access to ReproTracker through a subcontracting agreement, with testing conducted at Toxys.

The collaboration follows the publication of OECD Test Guideline 446A for ToxTracker in July 2026, providing a regulatory framework for the assay as a standardised method for identifying genotoxic hazards.

The partnership combines Toxys’ mechanistic in-vitro testing technologies with Charles River’s safety assessment capabilities, making the assays available to pharmaceutical, chemical, agrochemical and consumer product developers.

OECD recognition strengthens ToxTracker’s regulatory relevance

ToxTracker is a reporter gene assay designed to identify genotoxic hazards and provide mechanistic information about the biological processes involved.

Its OECD Test Guideline 446A recognition establishes a standardised approach for using the technology to assess genotoxicity. Validation studies have also demonstrated how its mechanistic information can help predict in-vivo genotoxicity outcomes and interpret equivocal or positive findings from established in-vitro assays.

This is relevant to pharmaceutical developers because identifying potential genetic toxicity earlier can help inform decisions during drug discovery and development.

ReproTracker uses human stem cells to assess developmental toxicity

The second technology, ReproTracker, uses human induced pluripotent stem cells (hiPSCs) to model aspects of early embryonic development and identify potential developmental toxicity hazards.

Unlike ToxTracker, which focuses on genetic damage, ReproTracker is designed to investigate potential effects on early development.

Under the expanded collaboration, Charles River will coordinate access to ReproTracker, while Toxys will perform the testing.

Together, the technologies offer complementary approaches to assessing different types of toxicity before or alongside conventional safety assessment studies.

Collaboration aims to advance non-animal testing

The companies said the expanded agreement would help make human-relevant testing methods more accessible to organisations developing pharmaceuticals and other products.

“Together with Charles River, we are helping drive the transition towards more predictive and human-relevant safety assessment,” said Giel Hendriks, chief executive officer of Toxys.

Charles River’s senior manager of business coordination DART, Allison Lintern, added: “Access to well-characterised, human-relevant tools is increasingly important for modern safety assessment.”

The collaboration is intended to support earlier identification of potential genetic and developmental toxicity findings and improve decision-making before conducting in-vivo studies.

Although NAMs are increasingly being incorporated into safety assessment, their suitability depends on the specific testing requirements and regulatory context. The expanded partnership aims to support wider adoption of these approaches while contributing to the reduction of animal testing where scientifically appropriate.

Mail Icon

news via inbox

Sign up for our newsletter and get the latest news right in your inbox